Effect of the Use of Bevacizumab in the Surgical Site on IOP After Trabeculectomy
Purpose
The purpose of this study of the trabeculectomy surgery rabbit model is to determine, which treatment modality between subconjunctival bevacizumab, intravitreal bevacizumab and subconjunctival 5-FU treatments is most effective in reducing IOP after surgery.
Methods
Forty-eight white New Zealand rabbits which were underwent standart trabeculectomy in the right eye, separated into 4 groups. In the postoperative period, balanced salt solution was injected into the bleb in group 1, bevacizumab was injected into the bleb in group 2 and into the vitreus in group 3, 5-FU injected into the non-bleb area in group 4. On post-operative days 1, 3, 5, 7, 11, 14, 17, 21, 24 and 28 IOP measurements were performed.
Results
Changes in mean IOP values of operated eyes were observed over time, and groups were compared. Mean IOP values of group 2 were lower than the other three groups. Mean IOP values of operated eyes within groups and mean IOP values of control eyes were compared and the change over time was observed. IOP values of operated eyes were statistically significantly lower than the control eyes during post-operative period up to day 11 for group 1, up to day 24 for group 2, up to day 17 for group 3 and up to day 14 for group 4.
Conclusion
Wound healing is the most important cause of surgical failure after trabeculectomy. This might lead to inability in controlling of IOP postoperatively. We have shown that the subconjunctival bevacizumab injection applied in the post-operative period has significantly lowered IOP and increased the success rate of trabeculectomy.